Avantor, Inc.

Avantor, Inc. announced its third quarter 2026 financial results, reporting net sales of $1,698.3 million, a 4.6% increase year-over-year, with organic growth of 5.2%. The company exceeded management's expectations for revenue and adjusted EPS. Avantor also raised its full-year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow, signaling improved performance and outlook. Both VWR Distribution & Services and Bioscience & Medtech Products segments contributed to the growth.

Avantor reported Q2 2026 net sales of $1,692.3 million, a slight increase from the prior year, but net income significantly decreased to $38.1 million, resulting in diluted EPS of $0.06. For the first half of 2026, net income was $81.4 million, down from $129.2 million in H1 2025. The company also disclosed ongoing securities class action and shareholder derivative lawsuits, which it intends to vigorously defend, and noted a goodwill impairment assessment was triggered in Q1 2026 due to market conditions, though no impairment was recorded.

Avantor, Inc. reported second quarter 2026 financial results, with net sales of $1,692.3 million, a 0.5% increase year-over-year, though organic sales declined by 0.4%. Net income was $38.1 million, and diluted GAAP EPS was $0.06, while adjusted EPS reached $0.21. The company exceeded its expectations for the quarter and subsequently increased its full-year 2026 organic revenue growth and adjusted EPS guidance, citing improved business performance and robust free cash flow used for debt repayment.

Avantor, Inc.'s wholly owned subsidiary, Avantor Funding, Inc., entered into Amendment No. 15 to its Credit Agreement. This amendment secured €374.2 million in new Incremental B-7 Euro Term Loans, which will refinance existing Euro term loans. The new loans carry a lower interest rate of EURIBO Rate plus 2.00%, compared to the previous rate of EURIBO Rate plus 2.50%, and mature on October 9, 2032.

Avantor, Inc. held its 2026 Annual Meeting of Stockholders on May 7, 2026. Stockholders elected nine directors for a one-year term, approved the 2025 compensation of named executive officers on an advisory basis, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026. The company's Board also determined to hold future advisory votes on executive compensation on an annual basis, in line with stockholder approval.

Avantor, Inc. reported flat net sales of $1,581.4 million for Q1 2026 compared to the prior year. Net income significantly decreased by 32.9% to $43.3 million, with diluted EPS falling to $0.06 from $0.09. The company also noted a sustained decline in its share price, triggering a goodwill impairment assessment, though no impairment was recorded this quarter, with a warning of potential future impairment.

Avantor, Inc. reported first-quarter 2026 financial results, with net sales of $1,581 million, flat compared to the prior year, though organic sales declined by 4.1%. Net income decreased to $43 million from $64.5 million in Q1 2025, and diluted GAAP EPS was $0.06. Adjusted EBITDA reached $219 million, and adjusted EPS was $0.17. The company generated $59 million in operating cash flow and $25 million in free cash flow. CEO Emmanuel Ligner noted that results exceeded expectations due to improved execution and stabilization in VWR, and the company reaffirmed its full-year 2026 guidance.

Avantor, Inc. announced the appointment of Ludovic Brellier as Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026. This strategic hire aims to support the company's integration activities. Concurrently, Benoit Gourdier, the former Executive Vice President, Bioscience and Medtech Products, will transition to a new role supporting segment integration before his expected departure from the company by December 31, 2026.